What tests and evaluations should be included in a comprehensive workup for cirrhosis?

Comprehensive Cirrhosis Workup

A cirrhosis workup should include determination of etiology through viral hepatitis serologies (HBV, HCV), ferritin and transferrin saturation, abdominal ultrasound, complete blood count, comprehensive metabolic panel with liver function tests, and prothrombin time/INR, followed by non-invasive fibrosis assessment and HCC surveillance in confirmed cases 1.

Initial Diagnostic Evaluation

Essential Laboratory Tests

The foundational workup begins with:

• Complete blood count (assess for thrombocytopenia suggesting portal hypertension)
• Comprehensive metabolic panel including AST, ALT, bilirubin, alkaline phosphatase, albumin
• Prothrombin time/INR and creatinine 2, 1
• Viral hepatitis serologies: HBsAg, anti-HCV antibodies 3, 4
• Iron studies: ferritin and transferrin saturation (screen for hemochromatosis) 5, 1

Imaging

Abdominal ultrasound is the primary imaging modality to assess for:

• Liver surface nodularity (particularly anterior left lobe)
• Atrophic right lobe with hypertrophied caudate and lateral segment
• Splenomegaly
• Intra-abdominal collaterals suggesting portal hypertension
• Ascites 6, 2, 1

Etiology-Specific Testing

Based on demographics and risk factors, additional testing includes:

• Alcohol history: Use AUDIT score; consider referral to alcohol services if AUDIT >19 7
• Metabolic syndrome markers: fasting glucose/HbA1c, lipid profile, waist circumference, BMI (for NAFLD) 2
• Autoimmune markers: ANA, ASMA, immunoglobulins (if other causes excluded) 7
• Alpha-1 antitrypsin level, ceruloplasmin (in appropriate clinical contexts) 1

Non-Invasive Fibrosis Assessment

Elastography is now the preferred method for confirming cirrhosis and avoiding liver biopsy in most cases 6, 8, 9:

• Vibration-controlled transient elastography (VCTE/FibroScan):

  • Cutoff ≥15 kPa generally confirms cirrhosis 1
  • Hepatitis C: 12.5 kPa cutoff (sensitivity 0.92, specificity 0.92) 8
  • Hepatitis B: 11.0 kPa cutoff 8
  • Alcoholic liver disease: 12.5 kPa cutoff 8

• Serum biomarker panels (when elastography unavailable):

  • FIB-4 score
  • APRI (AST-to-platelet ratio index)
  • Enhanced Liver Fibrosis (ELF) test 6, 1, 9

Important caveat: Obesity, active hepatitis, and cholestasis can falsely elevate elastography readings 6, 9. NAFLD patients with BMI >30 are often excluded from studies, limiting accuracy 8.

Liver Biopsy Indications

Biopsy is not routinely required but consider when 2, 7:

• Non-invasive tests are indeterminate or contradictory
• Etiology remains unclear after extended workup
• Autoimmune hepatitis suspected (may have normal autoantibodies)
• Results would alter management decisions
• Patient undergoing cholecystectomy or bariatric surgery (low-risk intraoperative biopsy)

Surveillance for Complications

Hepatocellular Carcinoma Screening

All patients with confirmed cirrhosis require HCC surveillance every 6 months 10, 4, 5:

• Abdominal ultrasound by experienced operator with dedicated equipment 10
• Alpha-fetoprotein (AFP) can be added but is optional (improves detection by 6-8% but increases false positives) 4
• When ultrasound is technically suboptimal, use MRI or CT 5

High-risk groups requiring HCC surveillance 10, 4:

• All cirrhosis from HBV, HCV, hemochromatosis
• Males with alcoholic cirrhosis (if abstinent/compliant)
• Males with primary biliary cirrhosis
• NASH cirrhosis (2-3% annual HCC risk) 2

Variceal Screening

• Esophagogastroduodenoscopy (EGD) to screen for esophageal varices 2
• Timing based on Child-Pugh class and platelet count

Additional Monitoring

• Child-Pugh and MELD scores calculated every 6 months 11
• Assess for ascites, hepatic encephalopathy, spontaneous bacterial peritonitis risk 12
• Screen for sarcopenia and nutritional deficiencies 13, 14

Common Pitfalls to Avoid

1. Do not rely on normal liver enzymes to exclude cirrhosis – ALT/AST may normalize in advanced disease 3
2. Do not use standard coagulation tests (INR, platelets) to guide bleeding risk – they poorly reflect actual hemostasis in cirrhosis; consider thromboelastography if available 15
3. Do not assume negative autoantibodies exclude autoimmune hepatitis – some cases are seronegative 7
4. Do not perform biopsy on potentially resectable HCC lesions – 1-3% risk of needle tract seeding 10
5. Do not stop HCC surveillance after achieving viral suppression – risk decreases but persists 3

Referral Criteria

Refer to hepatology/gastroenterology when 7:

• Advanced fibrosis confirmed (elastography >16 kPa or equivalent)
• Features of cirrhosis or portal hypertension on imaging
• Persistently elevated liver enzymes with negative workup
• Any evidence of decompensation (ascites, encephalopathy, variceal bleeding)
• MELD score ≥15 (transplant evaluation) 11

This algorithmic approach prioritizes early detection through non-invasive methods while ensuring appropriate surveillance to reduce morbidity and mortality from cirrhosis complications, particularly HCC and decompensation events.